Globus Medical Inc Stock News

Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO) said the U.S. Food and Drug

Globus Medical Inc''s (NYSE: GMED ) Q4 sales reached $250 million, +7.1% Y/Y (up 7.4% on a constant currency basis), beating the consensus of $243.52 million. The U.S. net sales, including robotics, increased by 7.2% to $212.96 million. International net sales increased by 6.8% and 8.7% on a constant currency basis, to $37.06 million. Sales from Musculoskeletal … Full story available on Benzinga.com

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

GMED earnings call for the period ending December 31, 2021.

GMED earnings call for the period ending December 31, 2021.

Globus Medical (GMED) delivered earnings and revenue surprises of 2.08% and 2.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical, Inc. (GMED) CEO David Demski on Q4 2021 Results - Earnings Call Transcript

Globus Medical press release (GMED): Q4 Non-GAAP EPS of $0.49 beats by $0.02.Revenue of $250.02M (+7.1% Y/Y) beats by $7M.Shares -0.51%.Non-GAAP adjusted EBITDA was $85.2 million,…

AUDUBON, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year

AUDUBON, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2021.

Globus Medical (GMED) delivered earnings and revenue surprises of 2.08% and 2.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma